Stephen B Williams1, Hogan K Hudgins2, Mohamed D Ray-Zack2, Karim Chamie3, Marc C Smaldone4, Stephen A Boorjian5, Siamak Daneshmand6, Peter C Black7, Ashish M Kamat8, Peter J Goebell9, Roland Seiler10, Bernd Schmitz-Drager9, Roman Nawroth11, Jacques Baillargeon12, Zachary Klaassen13, Girish S Kulkarni13, Simon P Kim14, Eugene K Lee15, Jeffrey M Holzbeierlein15, Brent K Hollenbeck16, John L Gore17. 1. Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA. Electronic address: stbwilli@utmb.edu. 2. Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA. 3. Department of Urology, University of California Los Angeles, Los Angeles, CA, USA. 4. Department of Urology, Fox Chase Cancer Center, Philadelphia, PA, USA. 5. Department of Urology, Mayo Clinic, Rochester, MN, USA. 6. USC Institute of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. 7. Department of Urologic Science, University of British Columbia, Vancouver, Canada. 8. Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 9. Department of Urology, Friedrich-Alexander University, Erlangen, Germany. 10. Department of Urology University Hospital Bern, Bern, Switzerland. 11. Department of Urology, Technical University of Munich, Munich, Germany. 12. Department of Medicine, Division of Epidemiology, Sealy Center on Aging, The University of Texas Medical Branch at Galveston, Galveston, TX, USA. 13. Department of Surgery, Division of Urology, University of Toronto, University Health Network, Princess Margaret Cancer Centre, Toronto, Canada. 14. Urology Institute, Center for Health Care Quality and Outcomes, University Hospitals Case Western Medical Center, Case Western Reserve University, Cleveland, OH, USA. 15. Department of Urology, The University of Kansas Medical Center, Kansas City, KS, USA. 16. Department of Urology, The University of Michigan, Ann Arbor, MI, USA. 17. Department of Urology, The University of Washington, Seattle, WA, USA.
Abstract
CONTEXT: Despite established guidelines for the treatment of muscle-invasive bladder cancer, it has been reported that radical cystectomy (RC) is markedly underused, especially among patients of advanced age and those with higher comorbidity burden and lower access to care. Understanding the interactions between patient, provider, and hospital factors may inform targeted interventions to optimize RC utilization. OBJECTIVE: To systematically review the literature regarding factors associated with RC utilization. EVIDENCE ACQUISITION: A systematic search was conducted using Ovid and Medline according to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines to identify studies between 1970 and 2017 reporting on RC utilization. Prospective and retrospective studies were included. EVIDENCE SYNTHESIS: There are no published randomized control trials on RC utilization. Variations in study quality and design precluded a formal statistical meta-analysis. RC receipt significantly depended on patient, provider, and hospital factors. Patient factors associated with lower RC use included advanced age, African American and Hispanic race/ethnicity, higher comorbidity burden, unmarried marital status, higher tumor stage and grade, and lower socioeconomic status. Provider factors associated with underutilization included lower surgeon volume and a metropolitan location. Finally, hospital factors associated with lower RC use included low hospital volume, nonacademic affiliation, and hospital location in the Midwest. CONCLUSIONS: RC is reportedly underutilized. We found that age, race, marital status, socioeconomic factors, cancer severity, comorbidity burden, surgeon volume, and facility type and location significantly determined RC receipt. Improved understanding of the varying contributions of the risk factors according to patient, provider, and hospital determinants may assist in developing targeted interventions to improve RC utilization. PATIENT SUMMARY: In this review we explored the clinical evidence for factors predicting the utilization of radical cystectomy for muscle-invasive bladder cancer. Many factors related to the patient, provider, and hospital determine whether patients receive this guideline-recommended treatment. However, there remains a lack of understanding on characterization and targeted interventions according to these levels, which may improve use.
CONTEXT: Despite established guidelines for the treatment of muscle-invasive bladder cancer, it has been reported that radical cystectomy (RC) is markedly underused, especially among patients of advanced age and those with higher comorbidity burden and lower access to care. Understanding the interactions between patient, provider, and hospital factors may inform targeted interventions to optimize RC utilization. OBJECTIVE: To systematically review the literature regarding factors associated with RC utilization. EVIDENCE ACQUISITION: A systematic search was conducted using Ovid and Medline according to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines to identify studies between 1970 and 2017 reporting on RC utilization. Prospective and retrospective studies were included. EVIDENCE SYNTHESIS: There are no published randomized control trials on RC utilization. Variations in study quality and design precluded a formal statistical meta-analysis. RC receipt significantly depended on patient, provider, and hospital factors. Patient factors associated with lower RC use included advanced age, African American and Hispanic race/ethnicity, higher comorbidity burden, unmarried marital status, higher tumor stage and grade, and lower socioeconomic status. Provider factors associated with underutilization included lower surgeon volume and a metropolitan location. Finally, hospital factors associated with lower RC use included low hospital volume, nonacademic affiliation, and hospital location in the Midwest. CONCLUSIONS:RC is reportedly underutilized. We found that age, race, marital status, socioeconomic factors, cancer severity, comorbidity burden, surgeon volume, and facility type and location significantly determined RC receipt. Improved understanding of the varying contributions of the risk factors according to patient, provider, and hospital determinants may assist in developing targeted interventions to improve RC utilization. PATIENT SUMMARY: In this review we explored the clinical evidence for factors predicting the utilization of radical cystectomy for muscle-invasive bladder cancer. Many factors related to the patient, provider, and hospital determine whether patients receive this guideline-recommended treatment. However, there remains a lack of understanding on characterization and targeted interventions according to these levels, which may improve use.
Authors: Marco Moschini; Evanguelos Xylinas; Stefania Zamboni; Agostino Mattei; Günter Niegisch; Evan Y Yu; Aristotelis Bamias; Neeraj Agarwal; Srikala S Sridhar; Cora N Sternberg; Ulka N Vaishampayan; Jonathan E Rosenberg; Joaquim Bellmunt; Matthew D Galsky; Francesco Montorsi; Andrea Necchi Journal: Eur Urol Oncol Date: 2019-07-13
Authors: Michael Froehner; Rainer Koch; Ulrike Heberling; Angelika Borkowetz; Matthias Hübler; Vladimir Novotny; Manfred P Wirth; Christian Thomas Journal: Eur Urol Open Sci Date: 2021-05-18